YALE-NEW HAVEN HOSPITAL
- Type
- Teaching hospital
- Where
- NEW HAVEN, CT
- Medicare CCN
- 070022
- Received
- $1,917,841 in 223 records, 2019 ($273,242 general, $1,644,598 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Nonprofit contractor: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Plan sponsor: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Federal award recipient: YALE NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Lobbying client: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying registrant: YALE-NEW HAVEN HOSPITAL Fuzzy (name and state)
- Nonprofit: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 53 | $273,242 |
| 2019 | Research payment | 170 | $1,644,598 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 170 | $1,644,598 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 21 | $77,506 |
| Education | 3 | $65,000 |
| Space rental or facility fees (teaching hospital only) | 6 | $60,000 |
| Grant | 11 | $33,177 |
| Gift | 8 | $32,044 |
| Charitable Contribution | 4 | $5,513 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $77,800 | Research payment | Cash or cash equivalent | Biograph mCT Flow Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | WBD PET imaging motion correction and population based IP | 2019 |
| 2019-12-31 | AngioDynamics, Inc. | $60,000 | Education | In-kind items and services | Nanoknife Device, Oncology Surgery | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $25,082 | Research payment | Cash or cash equivalent | SC2000 Device, US - Ultrasound Systems | Structural Heart Disease Investigation | 2019 |
| 2019-12-31 | Medartis Inc. | $13,642 | Gift (3 payments) | In-kind items and services | APTUS Device, ORTHO | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $1,406 | Research payment | Cash or cash equivalent | Yale2018MRIPR990Huber | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $990 | Research payment | Cash or cash equivalent | YaleNewHavenHosp2016MRIPR1023Huber | 2019 | |
| 2019-12-31 | Stryker Corporation | $958 | Gift | In-kind items and services | NSE - HIGH SPEED DRILLS Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $531 | Research payment | Cash or cash equivalent | YaleNewHavenHosp2019IPR925TurkBrowne | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $469 | Research payment | Cash or cash equivalent | YaleNewHavenHosp2018MRIPR1066Constable | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $326 | Research payment | Cash or cash equivalent | Yale2019MRIPR990Huber | 2019 | |
| 2019-12-18 | SEAGEN INC. | $1,580 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-12-18 | SEAGEN INC. | $1,170 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-12-17 | Bracco Diagnostics Inc. | $3,000 | Research payment | Cash or cash equivalent | PROHANCE Drug, CONTRAST MEDIA | AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVE | 2019 |
| 2019-12-11 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-12-05 | PTC Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE | 2019 | |
| 2019-12-05 | PTC Therapeutics, Inc. | $100 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE | 2019 | |
| 2019-12-03 | Intuitive Surgical, Inc. | $15,500 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-03 | Intuitive Surgical, Inc. | $800 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-03 | Intuitive Surgical, Inc. | $495 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-03 | Intuitive Surgical, Inc. | $30 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-03 | Intuitive Surgical, Inc. | $3 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-02 | Agios Pharmaceuticals, Inc. | $27,872 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | 2019 | |
| 2019-12-01 | Barco, Inc. | $614 | Gift | In-kind items and services | Diagnostic Displays Device, Diagnostic Imaging | 2019 | |
| 2019-11-25 | Lilly USA, LLC | $60,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-11-20 | SEAGEN INC. | $8,006 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-11-19 | Philips North America LLC | $3,500 | Research payment | Cash or cash equivalent | US Und Device, Cardiology/Vascular Diseases | VM 4.0 ECS PATIENT FEES | 2019 |
| 2019-11-18 | SEAGEN INC. | $26 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-11-14 | PTC Therapeutics, Inc. | $650 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE | 2019 | |
| 2019-11-13 | SEAGEN INC. | $6,319 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-11-07 | HOLOGIC INC | $13,725 | Research payment | Cash or cash equivalent | Dimensions Device, Breast and Skeletal Health | IIT | 2019 |
| 2019-11-06 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-11-05 | TESARO, Inc. | $1,670 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-11-05 | TESARO, Inc. | $1,595 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-11-05 | TESARO, Inc. | $975 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-11-01 | Bard Peripheral Vascular, Inc. | $260 | Research payment | Cash or cash equivalent | LUTONIX Device, PERIPHERAL VASCULAR | LUTONIX BTK TRIAL CL000501 | 2019 |
| 2019-10-30 | Cardiovascular Systems Inc. | $1,212 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-10-23 | Conformis, Inc. | $8,604 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2019 |
| 2019-10-23 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-10-22 | TESARO, Inc. | $26,791 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-10-22 | TESARO, Inc. | $3,900 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-10-22 | TESARO, Inc. | $3,150 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-10-21 | SEAGEN INC. | $36,576 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-10-21 | SEAGEN INC. | $20,861 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-10-21 | SEAGEN INC. | $2,158 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-10-21 | SEAGEN INC. | $1,644 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-10-18 | SEAGEN INC. | $13,814 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-10-18 | Mallinckrodt Enterprises LLC | $500 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-10-16 | SEAGEN INC. | $6,253 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-10-16 | SEAGEN INC. | $712 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-10-16 | SEAGEN INC. | $620 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-10-16 | SEAGEN INC. | $565 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-10-16 | SEAGEN INC. | $452 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-10-16 | SEAGEN INC. | $96 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-10-10 | HOLOGIC INC | $1,500 | Research payment | Cash or cash equivalent | Dimensions Device, Breast and Skeletal Health | IIT | 2019 |
| 2019-10-09 | SEAGEN INC. | $2,730 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-10-09 | SEAGEN INC. | $1,170 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-10-09 | Stryker Corporation | $1,133 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $595 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $58 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $42 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-08 | Cochlear Americas | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nucleus Device, Implantable hearing solution | 2019 | |
| 2019-10-04 | Mallinckrodt Enterprises LLC | $5,794 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-10-02 | Medical Device Business Services, Inc. | $1,500 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-10-01 | TESARO, Inc. | $7,152 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-10-01 | TESARO, Inc. | $3,479 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-09-27 | Amgen Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-09-27 | PTC Therapeutics, Inc. | $2,340 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE | 2019 | |
| 2019-09-26 | TESARO, Inc. | $10,859 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-09-26 | TESARO, Inc. | $7,923 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-09-26 | Bard Peripheral Vascular, Inc. | $1,500 | Research payment | Cash or cash equivalent | COVERA Device, PERIPHERAL VASCULAR | AVENEW BPV14005 | 2019 |
| 2019-09-26 | TESARO, Inc. | $178 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-09-24 | Bracco Diagnostics Inc. | $4,140 | Research payment | Cash or cash equivalent | PROHANCE Drug, CONTRAST MEDIA | AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVE | 2019 |
| 2019-09-19 | Mallinckrodt Enterprises LLC | $1,500 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-09-19 | Eli Lilly and Company | $43 | Research payment | In-kind items and services | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT | 2019 | |
| 2019-09-18 | SEAGEN INC. | $6,714 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-09-18 | Medical Device Business Services, Inc. | $1,500 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-09-10 | Bracco Diagnostics Inc. | $5,328 | Research payment | Cash or cash equivalent | CARDIOGEN-82 Drug, CONTRAST MEDIA | IMPACT OF RB82 PET ON HEALTH CARE ECONOMICS IN PATIENTS WITH ACUTE CHEST PAIN IN THE EMERGENCY DEPARTMENT. | 2019 |
| 2019-09-05 | Cardiovascular Systems Inc. | $1,500 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-09-05 | Cardiovascular Systems Inc. | $37 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-09-03 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-08-28 | AstraZeneca Pharmaceuticals LP | $33 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-08-22 | Philips North America LLC | $3,900 | Research payment | Cash or cash equivalent | US Und Device, Cardiology/Vascular Diseases | VM 4.0 ECS PATIENT FEES | 2019 |
| 2019-08-22 | PTC Therapeutics, Inc. | $390 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE | 2019 | |
| 2019-08-21 | SEAGEN INC. | $4,836 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-08-21 | Boston Scientific Corporation | $1,500 | Grant | Cash or cash equivalent | GENERAL - BRADY Device, BRADY | 2019 | |
| 2019-08-14 | Conformis, Inc. | $6,292 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2019 |
| 2019-08-13 | C. R. Bard, Inc. & Subsidiaries | $9,249 | Research payment | Cash or cash equivalent | ARCTIC SUN Device, MEDICAL SYSTEMS | INTREPID BMD1111 | 2019 |
| 2019-08-13 | C. R. Bard, Inc. & Subsidiaries | $1,148 | Research payment | In-kind items and services | ARCTIC SUN Device, MEDICAL SYSTEMS | INTREPID BMD1111 | 2019 |
| 2019-08-08 | Ipsen Biopharmaceuticals, Inc | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOMATULINE DEPOT Drug, Oncology/Endocrinology | 2019 | |
| 2019-08-07 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2019 | |
| 2019-08-06 | TESARO, Inc. | $390 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-08-01 | Cepheid | $49,300 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-08-01 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2019 | |
| 2019-07-30 | GE HEALTHCARE | $480 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-07-25 | Mallinckrodt Enterprises LLC | $5,814 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-07-25 | Cardiovascular Systems Inc. | $249 | Research payment | Cash or cash equivalent | Peripheral Orbital Atherectomy System Device, Atherectomy Device | LIBERTY 360 | 2019 |
| 2019-07-22 | SEAGEN INC. | $12,610 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-07-22 | PFIZER INC. | $400 | Research payment | Cash or cash equivalent | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY TOLERA | 2019 | |
| 2019-07-16 | SEAGEN INC. | $52,944 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-07-16 | SEAGEN INC. | $16,696 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-07-16 | SEAGEN INC. | $3,009 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-07-16 | Stryker Corporation | $1,279 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | SEAGEN INC. | $1,079 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-07-16 | Stryker Corporation | $493 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $58 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $57 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-11 | Conformis, Inc. | $26,000 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2019 |
| 2019-07-11 | Incyte Corporation | $2,500 | Education | Cash or cash equivalent | 2019 | ||
| 2019-07-11 | Cardiovascular Systems Inc. | $2,000 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-07-10 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-07-10 | SEAGEN INC. | $1,521 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-07-10 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-07-10 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-07-09 | TESARO, Inc. | $10,594 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-07-08 | Biogen, Inc. | $588 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion | 2019 | |
| 2019-07-05 | E.R. Squibb & Sons, L.L.C. | $5,500 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-07-05 | E.R. Squibb & Sons, L.L.C. | $1,100 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-07-02 | TESARO, Inc. | $48,344 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-07-02 | TESARO, Inc. | $7,281 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-07-02 | TESARO, Inc. | $2,271 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-07-02 | TESARO, Inc. | $1,988 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-07-02 | TESARO, Inc. | $1,332 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-07-02 | TESARO, Inc. | $1,052 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-07-02 | Cardiovascular Systems Inc. | $37 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-06-27 | TESARO, Inc. | $2,000 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-06-27 | TESARO, Inc. | $975 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-06-20 | Eisai Inc. | $5,000 | Grant | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-06-19 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-06-18 | Bracco Diagnostics Inc. | $6,070 | Research payment | Cash or cash equivalent | PROHANCE Drug, CONTRAST MEDIA | AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVE | 2019 |
| 2019-06-10 | Heron Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | HTX-011 Drug | Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) | 2019 |
| 2019-06-04 | Henry Schein, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2019 | ||
| 2019-06-03 | Lilly USA, LLC | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-05-30 | Medical Device Business Services, Inc. | $1,500 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-05-28 | Bolton Medical Inc | $10,140 | Research payment | Cash or cash equivalent | RelayPro-T IP-0018-16 Device, Endovascular | RelayPro-T IP-0018-16 | 2019 |
| 2019-05-28 | Bolton Medical Inc | $2,000 | Research payment | Cash or cash equivalent | RelayPro-T IP-0018-16 Device, Endovascular | RelayPro-T IP-0018-16 | 2019 |
| 2019-05-28 | Bolton Medical Inc | $1,950 | Research payment | Cash or cash equivalent | RelayPro-T IP-0018-16 Device, Endovascular | RelayPro-T IP-0018-16 | 2019 |
| 2019-05-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | $622 | Research payment | In-kind items and services | Phase I/II monotherapy of low risk MDS | 2019 | |
| 2019-05-23 | E.R. Squibb & Sons, L.L.C. | $10,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-05-23 | Cardiovascular Systems Inc. | $3,000 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-05-22 | Celgene Corporation | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-05-20 | Cepheid | $2,522 | Research payment | In-kind items and services | 2019 | ||
| 2019-05-13 | McKesson Corporation | $2,500 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-05-09 | Mallinckrodt Enterprises LLC | $2,000 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-05-08 | SEAGEN INC. | $19,773 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-05-06 | SEAGEN INC. | $43,873 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-05-02 | Cardiovascular Systems Inc. | $56 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-04-29 | HOLOGIC INC | $3,500 | Research payment | Cash or cash equivalent | Dimensions Device, Breast and Skeletal Health | IIT | 2019 |
| 2019-04-24 | Medtronic USA, Inc. | $2,871 | Grant | In-kind items and services | 2019 | ||
| 2019-04-22 | SEAGEN INC. | $17,890 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-04-18 | SEAGEN INC. | $108,684 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-04-18 | SEAGEN INC. | $38,395 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-04-18 | SEAGEN INC. | $22,025 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-04-18 | SEAGEN INC. | $15,260 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-04-17 | Mallinckrodt Enterprises LLC | $4,435 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-04-12 | Stryker Corporation | $1,142 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $427 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $64 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $59 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-11 | Genentech USA, Inc. | $35,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Alecensa Biological, BioOncology | 2019 | |
| 2019-04-10 | SEAGEN INC. | $4,500 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-04-10 | SEAGEN INC. | $2,171 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-04-10 | SEAGEN INC. | $1,170 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-04-10 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2019 | |
| 2019-04-08 | Lilly USA, LLC | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-04-04 | Cardiovascular Systems Inc. | $50 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-04-03 | McKesson Corporation | $2,500 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-04-03 | SEAGEN INC. | $495 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-04-01 | SEAGEN INC. | $6,630 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-04-01 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-04-01 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-03-31 | Abbott Laboratories | $38 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-03-28 | Conformis, Inc. | $13,640 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2019 |
| 2019-03-27 | C. R. Bard, Inc. & Subsidiaries | $42,412 | Research payment | Cash or cash equivalent | ARCTIC SUN Device, MEDICAL SYSTEMS | INTREPID BMD1111 | 2019 |
| 2019-03-27 | SEAGEN INC. | $3,663 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-03-27 | SEAGEN INC. | $3,338 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-03-27 | Bard Peripheral Vascular, Inc. | $1,560 | Research payment | Cash or cash equivalent | VERNACULAR BPV14007 | 2019 | |
| 2019-03-27 | SEAGEN INC. | $780 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-03-21 | Mallinckrodt Enterprises LLC | $5,391 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-03-20 | Diagnostica Stago, Inc | $233,063 | Research payment | Cash or cash equivalent | Device, Hemostasis | 2019 | |
| 2019-03-20 | SEAGEN INC. | $2,200 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-03-20 | SEAGEN INC. | $671 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-03-19 | TESARO, Inc. | $2,562 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-03-19 | TESARO, Inc. | $1,052 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV | 2019 | |
| 2019-03-14 | Conformis, Inc. | $32,500 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2019 |
| 2019-03-06 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-03-04 | SEAGEN INC. | $1,170 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-02-27 | SEAGEN INC. | $4,407 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-02-27 | SEAGEN INC. | $2,500 | Education | Cash or cash equivalent | ADCETRIS Biological, Oncology | 2019 | |
| 2019-02-27 | SEAGEN INC. | $1,300 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-02-27 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-02-27 | SEAGEN INC. | $247 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,043 | Research payment | In-kind items and services | Phase I BI907828 in advance TP53WT MDM2 amplified | 2019 | |
| 2019-02-25 | Medical Device Business Services, Inc. | $695 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-02-22 | PROGENICS PHARMACEUTICALS, INC. | $28,340 | Research payment | In-kind items and services | Study of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR | 2019 | |
| 2019-02-22 | PROGENICS PHARMACEUTICALS, INC. | $12,155 | Research payment | In-kind items and services | Study of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR | 2019 | |
| 2019-02-21 | Mallinckrodt Enterprises LLC | $423 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-02-19 | SEAGEN INC. | $780 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-02-15 | PROGENICS PHARMACEUTICALS, INC. | $34,357 | Research payment | In-kind items and services | Study of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR | 2019 | |
| 2019-02-15 | PROGENICS PHARMACEUTICALS, INC. | $4,741 | Research payment | In-kind items and services | Study of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR | 2019 | |
| 2019-02-11 | PFIZER INC. | $103 | Research payment | Cash or cash equivalent | A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTY OPEN PLACEBOCONTROLLED DOSE ESCALATING STUDY TO EVALUATE THE SAFETY TOLERABI | 2019 |
The latest 200 records of 223.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) New Haven, CT | County South Central Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 134,349 | 570,598 | 3,624,508 |
| Population, 2020 census P1 | 134,023 | - | 3,605,944 |
| Median age B01002 | 31.9 | 40.2 | 41.1 |
| Under 18 B01001 | 21.3% | 19.6% | 20.2% |
| 65 and over B01001 | 11.8% | 18.6% | 18.5% |
| Households B11001 | 54,773 | 230,673 | 1,434,007 |
| Foreign born B05002 | 18.0% | 13.7% | 15.7% |
| Median household income B19013 | $56,851 | $88,197 | $95,781 |
| Median family income B19113 | $68,668 | $115,384 | $122,706 |
| Per capita income B19301 | $36,242 | $49,766 | $55,915 |
| Poverty rate B17001 | 23.9% | 11.4% | 10.0% |
| Unemployment rate B23025 | 8.4% | 6.0% | 5.6% |
| Civilian labor force B23025 | 69,528 | 307,607 | 1,959,490 |
| Mean commute (minutes) B08013 | 21.5 | 23.5 | 26.5 |
| Bachelor's degree or higher B15003 | 38.9% | 42.0% | 42.5% |
| Housing units B25001 | 60,333 | 248,267 | 1,541,822 |
| Owner-occupied B25003 | 28.4% | 60.5% | 66.5% |
| Renters B25003 | 71.6% | 39.5% | 33.5% |
| Median home value B25077 | $287,100 | $353,100 | $366,900 |
| Median gross rent B25064 | $1,488 | $1,525 | $1,488 |
| White, not Hispanic B03002 | 30.0% | 58.5% | 61.9% |
| Black B03002 | 27.6% | 13.0% | 9.8% |
| Hispanic or Latino B03002 | 31.0% | 19.5% | 18.3% |
| Asian B03002 | 5.2% | 4.5% | 4.7% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.
Comments